<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380548</url>
  </required_header>
  <id_info>
    <org_study_id>eki-396</org_study_id>
    <nct_id>NCT01380548</nct_id>
  </id_info>
  <brief_title>Effects of 5-Aminolevulinic Acid on Iron Deficiency Anemia</brief_title>
  <official_title>A Double-blind, Placebo Controlled Study to Assess Efficacy of 5-Aminolevulinic Acid in Subjects With Iron Deficiency Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hiroshima University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SBI ALApromo Co., Ltd., Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hiroshima University</source>
  <brief_summary>
    <textblock>
      This study is designed to evaluate efficacy and dose-dependency of 5-aminolevulinic acid in
      subjects with iron deficiency anemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>Every 4 weeks (Overall 20 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum ferritin level</measure>
    <time_frame>Every 4 weeks (Overall 20 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin level</measure>
    <time_frame>Every 4 weeks (Overall 20 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCV level</measure>
    <time_frame>Every 4 weeks (Overall 20 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIBC level</measure>
    <time_frame>Every 4 weeks (Overall 20 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulocyte level</measure>
    <time_frame>Every 4 weeks (Overall 20 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell level</measure>
    <time_frame>Every 4 weeks (Overall 20 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit level</measure>
    <time_frame>Every 4 weeks (Overall 20 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum iron level</measure>
    <time_frame>Every 4 weeks (Overall 20 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble transferrin receptor level</measure>
    <time_frame>Week 0 (baseline) and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepcidin-25 level</measure>
    <time_frame>Week 0 (baseline) and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose 5-aminolevulinic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium-dose 5-aminolevulinic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose 5-aminolevulinic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo; once/day; for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Iron alone</intervention_name>
    <description>Iron (3 mg); once/day; for 12 weeks</description>
    <arm_group_label>Iron alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low-dose 5-aminolevulinic acid with iron</intervention_name>
    <description>5-Aminolevulinic acid (12.5 mg) and iron (3 mg); once/day; for 12 weeks</description>
    <arm_group_label>Low-dose 5-aminolevulinic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Medium-dose 5-aminolevulinic acid with iron</intervention_name>
    <description>5-Aminolevulinic acid (25 mg) and iron (3 mg); once/day; for 12 weeks</description>
    <arm_group_label>Medium-dose 5-aminolevulinic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High-dose 5-aminolevulinic acid with iron</intervention_name>
    <description>5-Aminolevulinic acid (50 mg) and iron (3 mg); once/day; for 12 weeks</description>
    <arm_group_label>High-dose 5-aminolevulinic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women with hemoglobin ≥ 9.0 g/dl and ≤ 12.0 g/dl

          -  Willing not to donate blood during the study

          -  Informed consent signed

        Exclusion Criteria:

          -  History of porphyria, hemochromatosis, or viral hepatitis

          -  Anemia other than iron deficiency

          -  BMI ≤ 18 kg/m2 or ≥ 30 kg/m2

          -  Pregnant or nursing a child

          -  Participation in any clinical trial within 90 days of the commencement of the trial

          -  Renal or hepatic dysfunction

          -  Heart disease

          -  Subjects who are taking medicines or functional food that may affect hemoglobin level
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hiroshima University</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>March 26, 2013</last_update_submitted>
  <last_update_submitted_qc>March 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hiroshima University</investigator_affiliation>
    <investigator_full_name>Fumiko Higashikawa</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

